Cargando…

Immunosuppression-associated posterior reversible encephalopathy syndrome in an acute leukemia case

Posterior reversible encephalopathy syndrome (PRES) was described in 1996. Herein, we aimed to report an immunosuppression- related PRES case. A 34-year-old woman was diagnosed as t-cell acute lymphoblastic leukemia and allogeneic hematopoietic stem cell transplantation (HSCT) was performed. Cyclosp...

Descripción completa

Detalles Bibliográficos
Autores principales: Malkan, Umit Y., Gunes, Gursel, Demiroglu, Haluk, Goker, Hakan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications, Pavia, Italy 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6240836/
https://www.ncbi.nlm.nih.gov/pubmed/30542527
http://dx.doi.org/10.4081/hr.2018.7257
_version_ 1783371700774109184
author Malkan, Umit Y.
Gunes, Gursel
Demiroglu, Haluk
Goker, Hakan
author_facet Malkan, Umit Y.
Gunes, Gursel
Demiroglu, Haluk
Goker, Hakan
author_sort Malkan, Umit Y.
collection PubMed
description Posterior reversible encephalopathy syndrome (PRES) was described in 1996. Herein, we aimed to report an immunosuppression- related PRES case. A 34-year-old woman was diagnosed as t-cell acute lymphoblastic leukemia and allogeneic hematopoietic stem cell transplantation (HSCT) was performed. Cyclosporine was given for GVHD prophylaxis in addition to the other routine medications of HSCT. She was hospitalized for acute renal failure and due to the possible contribution of acute renal failure cyclosporine was stopped. Tacrolimus was started for GVHD prophylaxis at a dose of 1 mg/day. However, fifteen days after the initiation of tacrolimus, blurred vision occurred in our patient. Petechial bleeding sites were detected in bilateral cerebral and cerebellar hemisphere by MR imaging. Tacrolimus dosage was reduced to 0.5 mg/day. She had hypertension which was difficult to control and followed-up in the intensive care unit. She had seizures. Control cranial MR resulted as diffusion limitation in bilateral cerebellar hemisphere, bilateral occipital and frontal-parietal regions with vasogenic edema findings; contrast involvement in left frontal-parietal and right cerebellar regions. She had vision loss and lethargy. Control cranial MR favored PRES syndrome secondary to immunosuppression. Hypertensive state was taken under control with antihypertensive treatment and all immunosuppressive agents were stopped. Two weeks later her clinical condition was slightly improved. MR test which was conducted 2 weeks after the diagnosis revealed the regression of PRES lesions. The characteristic signs on neuroimaging are the symmetrical white matter edema in the posterior cerebral hemispheres, particularly the parietal- occipital regions. In conclusion, PRES rarely develops secondary to the immunosuppressive agents and the clinicians should suspect and promptly diagnose PRES which might cause otherwise serious irreversible clinical complications.
format Online
Article
Text
id pubmed-6240836
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher PAGEPress Publications, Pavia, Italy
record_format MEDLINE/PubMed
spelling pubmed-62408362018-12-12 Immunosuppression-associated posterior reversible encephalopathy syndrome in an acute leukemia case Malkan, Umit Y. Gunes, Gursel Demiroglu, Haluk Goker, Hakan Hematol Rep Case Report Posterior reversible encephalopathy syndrome (PRES) was described in 1996. Herein, we aimed to report an immunosuppression- related PRES case. A 34-year-old woman was diagnosed as t-cell acute lymphoblastic leukemia and allogeneic hematopoietic stem cell transplantation (HSCT) was performed. Cyclosporine was given for GVHD prophylaxis in addition to the other routine medications of HSCT. She was hospitalized for acute renal failure and due to the possible contribution of acute renal failure cyclosporine was stopped. Tacrolimus was started for GVHD prophylaxis at a dose of 1 mg/day. However, fifteen days after the initiation of tacrolimus, blurred vision occurred in our patient. Petechial bleeding sites were detected in bilateral cerebral and cerebellar hemisphere by MR imaging. Tacrolimus dosage was reduced to 0.5 mg/day. She had hypertension which was difficult to control and followed-up in the intensive care unit. She had seizures. Control cranial MR resulted as diffusion limitation in bilateral cerebellar hemisphere, bilateral occipital and frontal-parietal regions with vasogenic edema findings; contrast involvement in left frontal-parietal and right cerebellar regions. She had vision loss and lethargy. Control cranial MR favored PRES syndrome secondary to immunosuppression. Hypertensive state was taken under control with antihypertensive treatment and all immunosuppressive agents were stopped. Two weeks later her clinical condition was slightly improved. MR test which was conducted 2 weeks after the diagnosis revealed the regression of PRES lesions. The characteristic signs on neuroimaging are the symmetrical white matter edema in the posterior cerebral hemispheres, particularly the parietal- occipital regions. In conclusion, PRES rarely develops secondary to the immunosuppressive agents and the clinicians should suspect and promptly diagnose PRES which might cause otherwise serious irreversible clinical complications. PAGEPress Publications, Pavia, Italy 2018-11-06 /pmc/articles/PMC6240836/ /pubmed/30542527 http://dx.doi.org/10.4081/hr.2018.7257 Text en ©Copyright U.Y. Malkan et al., 2018 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Case Report
Malkan, Umit Y.
Gunes, Gursel
Demiroglu, Haluk
Goker, Hakan
Immunosuppression-associated posterior reversible encephalopathy syndrome in an acute leukemia case
title Immunosuppression-associated posterior reversible encephalopathy syndrome in an acute leukemia case
title_full Immunosuppression-associated posterior reversible encephalopathy syndrome in an acute leukemia case
title_fullStr Immunosuppression-associated posterior reversible encephalopathy syndrome in an acute leukemia case
title_full_unstemmed Immunosuppression-associated posterior reversible encephalopathy syndrome in an acute leukemia case
title_short Immunosuppression-associated posterior reversible encephalopathy syndrome in an acute leukemia case
title_sort immunosuppression-associated posterior reversible encephalopathy syndrome in an acute leukemia case
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6240836/
https://www.ncbi.nlm.nih.gov/pubmed/30542527
http://dx.doi.org/10.4081/hr.2018.7257
work_keys_str_mv AT malkanumity immunosuppressionassociatedposteriorreversibleencephalopathysyndromeinanacuteleukemiacase
AT gunesgursel immunosuppressionassociatedposteriorreversibleencephalopathysyndromeinanacuteleukemiacase
AT demirogluhaluk immunosuppressionassociatedposteriorreversibleencephalopathysyndromeinanacuteleukemiacase
AT gokerhakan immunosuppressionassociatedposteriorreversibleencephalopathysyndromeinanacuteleukemiacase